- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04595799
Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis. (MSST)
MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system for which the investigators now have many treatment alternatives. These treatments have a preventive goal and the data in the literature suggest the interest in rapidly achieving optimal control of the disease in order to decrease the risk of long-term disability progression.
One of the current unmet needs is to have markers that can be used at the individual level to predict the long-term prognosis in order to propose optimal and personalized therapeutic management.
Classically used clinical markers do not meet this need. It is recognized that there is a so-called silent course of MS (not measurable by clinical parameters), which may, after several months or years, be expressed as a physical or cognitive disability.
MRI is the reference examination for monitoring the sub-clinical activity of the disease but it does not allow the neurodegenerative side of the disease to be assessed. Other blood or imaging markers are being studied but are not yet usable in daily practice.
The project aims to evaluate the interest in using digital biomarkers, based on a rapid assessment of patients using a locally developed mobile application (MS Screen Test - MSST) to predict the evolutionary prognosis of the disease.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: MIKAEL COHEN
- Telefonnummer: 334 92 03 82 52
- E-post: cohen.m@chu-nice.fr
Studieorter
-
-
-
Lille, Frankrike, 59037
- Rekrytering
- Lille University Hospital
-
Kontakt:
- Helene ZEPHIR
- E-post: Thi-helene.ZEPHIR@CHRU-LILLE.FR
-
Underutredare:
- Helene ZEPHIR
-
Lyon, Frankrike, 69000
- Rekrytering
- LYON Civil Hospital
-
Montpellier, Frankrike, 34295
- Rekrytering
- Montpellier University Hospital
-
Kontakt:
- pierre LABAUGE
- E-post: p-labauge@chu-montpellier.fr
-
Nice, Frankrike, 06000
- Rekrytering
- Nice University Hospital
-
Kontakt:
- MIKAEL COHEN
- Telefonnummer: 334 92 03 82 52
- E-post: cohen.m@chu-nice.fr
-
Huvudutredare:
- mikael COHEN
-
Nîmes, Frankrike, 30900
- Rekrytering
- Nîmes University Hospital
-
Kontakt:
- eric THOUVENOT
- E-post: eric.thouvenot@chu-nimes.fr
-
Huvudutredare:
- Eric THOUVENOT
-
Paris, Frankrike, 75013
- Rekrytering
- Paris University Hospital - la pitié salpétriere
-
Kontakt:
- Elisabeth MAILLART
- E-post: elisabeth.maillart@aphp.fr
-
Huvudutredare:
- elisabeth MAILLART
-
Rennes, Frankrike, 35033
- Rekrytering
- Rennes University Hospital
-
Underutredare:
- Emmanuelle Lepage
-
Rouen, Frankrike, 76031
- Rekrytering
- Rouen University Hospital
-
Kontakt:
- Bertrand BOURRE
- E-post: Bertrand.Bourre@chu-rouen.fr
-
Strasbourg, Frankrike, 67000
- Rekrytering
- Strasbourg University Hospital
-
Kontakt:
- Jerome De SEZE
- E-post: Jerome.DESEZE@chru-strasbourg.fr
-
Toulouse, Frankrike, 31059
- Rekrytering
- Toulouse University Hospital
-
Kontakt:
- Jonathan CIRON
- E-post: ciron.j@chu-toulouse.fr
-
Huvudutredare:
- Jonathan CIRON
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patient between 18 and 60 years of age
- Presenting a diagnosis of relapsing-remitting MS defined according to McDonald 2017 criteria confirmed within 6 months prior to inclusion
- Starting first-line treatment (interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate)
- Having an encephalic and cervical MRI in OFSEP format, within 6 months prior to inclusion
- No relapse within 30 days prior to inclusion
Exclusion Criteria:
- presence of a motor, visual or cognitive deficit not related to MS
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
speed test in MMST results
Tidsram: 12 months
|
the average speed (in taps per second or Hz) for the dominant and non-dominant hand
|
12 months
|
agility test in MMST results
Tidsram: 12 months
|
time required (in seconds) to bring the ball to the target as well as the actual time the ball will be held inside the target (expressed as a percentage of the total recording time)
|
12 months
|
synchronization test in MMST results
Tidsram: 12 months
|
the average time interval expressed in milliseconds separating the left and right index strokes.
|
12 months
|
visual test in MMST results
Tidsram: 12 months
|
number of letters seen
|
12 months
|
Cognitive test in MMST results
Tidsram: 12 months
|
the average response latency (the time in milliseconds between the display and the click on a good answer) expressed in milliseconds, the number of wrong answers as well as the number of missed letters. the average response latency is the combination of multiple measurements (time of response, number of wrong answers and number of missed letters. |
12 months
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 20-AOI-01
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Multipel skleros
-
Centre Hospitalier Universitaire de NīmesAvslutadMonckeberg Medial Calcific SclerosisFrankrike
-
Assistance Publique - Hôpitaux de ParisOkändArteriosclerosis Obliterans | Diabetiska vaskulära sjukdomar | Monckeberg Medial Calcific SclerosisFrankrike
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeKlassiskt Hodgkin lymfom | Lymfocytrikt klassiskt Hodgkin-lymfom | Ann Arbor stadium IB Hodgkin lymfom | Ann Arbor stadium II Hodgkin lymfom | Ann Arbor stadium IIA Hodgkin lymfom | Ann Arbor stadium IIB Hodgkin lymfom | Ann Arbor stadium I Hodgkin lymfom | Ann Arbor Steg I blandad cellularitet Klassiskt... och andra villkorFörenta staterna